awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q36544516-19A3D9DC-18CC-4E35-8747-6557405EF933
Q36544516-19A3D9DC-18CC-4E35-8747-6557405EF933
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36544516-19A3D9DC-18CC-4E35-8747-6557405EF933
HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide
P2860
Q36544516-19A3D9DC-18CC-4E35-8747-6557405EF933
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36544516-19A3D9DC-18CC-4E35-8747-6557405EF933
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
5c492517c6803aeab246a5eb19968be028d67f49
P2860
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.